<DOC>
	<DOCNO>NCT02321878</DOCNO>
	<brief_summary>This trial conduct Asia . The aim trial evaluate safety effectiveness Victoza® patient type 2 diabetes mellitus ( T2DM ) combination antidiabetes agent sulfonylurea post-marketing normal clinical practice condition .</brief_summary>
	<brief_title>Post-marketing Surveillance ( Special Use-results Surveillance ) Use With Liraglutide ( Victoza® )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Informed consent obtain studyrelated activity ( Studyrelated activity procedure relate recording data accord protocol ) Patients T2DM ( type 2 diabetes mellitus ) physician decide start treatment Victoza® combination insulin OAD ( oral antidiabetes drug ) SU ( sulfonylurea ) Male female , age limitation Previous participation study NN22113772 Participation define informed consent obtain study enrolment NN22113772 Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation Patients Victoza® previously Victoza® within 3 month enrolment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>